J9354Inj, ado-trastuzumab emt 1mg
Published CMS Medicare Part B payment-limit context for J9354, with recent quarterly history and calculated package-level strength context from the CMS crosswalk.
CMS payment limit
$43.626
per 1 MG · Medicare Part B
Up 3.4%from $42.198 in 2026-Q2
- Current quarter
- Billing unit
Payment limit over time
$44.0713$39.9997
2024-Q4: $40.445; 2025-Q1: $40.968; 2025-Q2: $41.105; 2025-Q3: $41.854; 2025-Q4: $42.16; 2026-Q1: $42.193; 2026-Q2: $42.198; 2026-Q3: $43.626
No current FDA shortage matchThe latest completed FDA data has no affected record matching the Trastuzumab Emtansine ingredient family (FDA data as of August 20, 2026).
Kadcyla
Package figures are calculated from the CMS per-unit payment limit × billable units per package; they are not CMS-published package-level payment limits.
Presentation updates
Put another code on your radar.
Browse the CMS directory for published payment-limit context across drugs, NDCs, and source-backed HCPCS Level II drug codes.